A team at the Institute of Cellular Biology and Pathology ‘Nicolae Simionescu’ of Romanian Academy aimed to assess the effects of targeted siRNA for AP-1 silencing on restoring structural...
Immuno Technologies Inc. and affiliated organizations have published preclinical data on a novel parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease.
Researchers from the Virginia-Maryland College of Veterinary Medicine have developed a new murine model of Eastern equine encephalitis virus infection that resembles human disease with its associated neurologic sequelae.
MYC oncogene is known to be amplified in 5% to 10% and overexpressed in 20% of clear cell renal cell carcinoma (ccRCC), conferring aggressiveness. Researchers have now found...
Previous research has shown that upon activation, platelets release CXCL4, influencing replication and propagation of dengue virus (DENV) by increasing the capacity of DENV-2 subtype to bind the CXCR3 receptor on monocytes. At the recent Viruses conference held in Barcelona, researchers from the Translational Health Science & Technology Institute reported the preclinical profile of a CXCR3 antagonist under investigation for the treatment of DENV.
Immunoglobulin G (IgG), an antibody that participates in the response to infection, could have a specific role in metabolism. During aging, it accumulates in certain tissues inducing metabolic dysfunction and fibrosis of fat tissue. This effect could be prevented through an intracellular receptor that contributes to the delivery of IgG. A team of researchers from Columbia University and Peking University (PKU) demonstrated that reducing excess IgG improved the metabolic health of aged mice and increased their life expectancy.
Chiesi Farmaceutici SpA has detailed new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Work at Abbisko Therapeutics Co. Ltd. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors potentially useful for the treatment of cancer.
Shouyao Holdings (Beijing) Co. Ltd. has patented tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer and Noonan syndrome.
RSS
